Valdecoxib IMpurity-E
- CAS NO.:1373038-63-1
- Empirical Formula: C16H11Cl2NO5S2
- Molecular Weight: 432.3
- MDL number: MFCD30543697
- Update Date: 2025-07-16 09:55:29
What is Valdecoxib IMpurity-E?
The Uses of Valdecoxib IMpurity-E
3-[4-[4-(Chlorosulfonyl)phenyl]-5-methyl-3-isoxazolyl]benzenesulfonyl Chloride is a reagent for the synthesis of Valdecoxib, a non steroidal anti-inflammatory drug.
Properties of Valdecoxib IMpurity-E
| Boiling point: | 549.1±50.0 °C(Predicted) |
| Density | 1.513±0.06 g/cm3(Predicted) |
| pka | -5.41±0.50(Predicted) |
Safety information for Valdecoxib IMpurity-E
Computed Descriptors for Valdecoxib IMpurity-E
New Products
2-(2-Chlorophenyl)glycine Propiolic Acid 1-(3-Hydroxy-4-methoxyphenyl)-2-nitroethene (±)-amino(2-fluorophenyl)acetic acid trans-3-Benzyloxy-4-methoxy-beta-nitrostyrene 1-Pentadecanol 4-(4-Αminophenyl)-3-Morpholinone 3-Morpholino-1-(4-(2-oxopiperidin-1-yl) phenyl)-5,6-dihyropyridin-2-(1H)-one 1-(4-Aminophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one N-cyanoacetylurethane 1H-IndazoleRelated products of tetrahydrofuran


![AcotiaMide Related CoMpound (Ethyl 2-[(2-hydroxy-4,5-diMethoxybenzoyl)aMino]-4-Thiazolecarboxylate)](https://img.chemicalbook.in/CAS/20200515/GIF/185106-05-2.gif)





You may like
-
40216-83-9 trans-4-Hydroxy-L-proline methyl ester hydrochloride 98+View Details
40216-83-9 -
471-25-0 Propiolic Acid 98+View Details
471-25-0 -
84145-28-8 98+View Details
84145-28-8 -
trans-3-Benzyloxy-4-methoxy-beta-nitrostyrene 98+View Details
63909-29-5 -
2-(2-Chlorophenyl)glycine 88744-36-9 98+View Details
88744-36-9 -
40216-83-9 trans-4-Hydroxy-L-proline methyl ester hydrochloride 98+View Details
40216-83-9 -
629-76-5 98+View Details
629-76-5 -
1-(3-Hydroxy-4-methoxyphenyl)-2-nitroethene 98+View Details
39816-35-8
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
